GLOBAL BLOOD THERAPEUTICS, INC.

GLOBAL BLOOD THERAPEUTICS, INC. specializes in the manufacturing of pharmaceutical preparations, with demonstrated expertise in the development and production of oral solid dosage forms, including tablets for targeted therapeutic applications. Their technical capabilities center on GMP-compliant pharmaceutical manufacturing processes, formulation science, and quality assurance systems aligned with FDA regulatory standards. The company’s specialization in voxelotor, a small-molecule hemoglobin modulator, reflects advanced proficiency in hematologic therapeutics, including drug substance integration, tablet coating technologies, and stability-driven production workflows. Their ability to deliver complex, precision-engineered pharmaceutical products positions them as a niche supplier in the treatment of chronic blood disorders. The contractor has delivered pharmaceutical products under a contract with the Department of Justice, indicating engagement in government-funded therapeutic programs, potentially related to correctional healthcare or specialized medical supply chains. This relationship suggests experience navigating federal procurement protocols for controlled or high-integrity pharmaceuticals, though the scope remains focused on product delivery rather than clinical or logistical services. The primary NAICS code 325412 reflects core competency in pharmaceutical preparation manufacturing, specifically the formulation, blending, compression, and packaging of finished drug products. The company’s market positioning is anchored in specialty pharmaceuticals, with a focus on orphan or niche indications requiring stringent process controls and regulatory adherence. Their vertical specialization lies in hematologic therapeutics, distinguishing them from broad-spectrum manufacturers. As a 2L entity headquartered in South San Francisco, California, GLOBAL BLOOD THERAPEUTICS, INC. operates as a mid-sized biopharmaceutical manufacturer without federal certifications such as 8(a), HUBZone, or WOSB. Their geographic presence is concentrated in the Bay Area’s biotech corridor, aligning them with innovation-driven federal suppliers in the life sciences sector.